WhatsApp
backNews Article

Zydus Lifesciences Achieves ₹79.1 Billion Revenue in Q2 FY27 with 29% YoY Growth and Expands Specialty Pharmaceutical Portfolio

Strong double-digit growth across India, international markets and North America segments supports 24% EBITDA margin amid US Saroglitazar launch investments

Zydus Lifesciences posted consolidated revenues of ₹79.1 billion for Q2 FY27, marking a 29% year-on-year increase. The company maintained a robust EBITDA margin of 24% despite ongoing investments in the US Saroglitazar launch, with net profit reaching ₹9.3 billion. Key segments such as India branded formulations, international markets, North American generics and specialty businesses, and consumer wellness showed strong double-digit growth during the quarter.

07 Nov 2026|ZYDUSLIFE-0.25%
Zydus Lifesciences Limited532321ZYDUSLIFEEarnings Call Transcript

Zydus Lifesciences Limited

Earnings Call Transcript

Zydus Lifesciences reported consolidated revenues of ₹79.1 billion for the second quarter ended September 30, 2026, representing a 29% year-on-year increase. The company recorded an EBITDA margin of 24% despite ongoing investment in Saroglitazar launch activities in the United States, with net profit at ₹9.3 billion.

The India branded formulations business grew 19% year-on-year, outperforming the Indian pharmaceutical market with a 20% increase in secondary sales mainly driven by volume and new product launches. Key therapy areas contributing to growth included cardiology, diabetology, respiratory, dermatology, gastrointestinal, anti-infectives, oncology, and nephrology.

International markets formulations revenue increased by 33% year-on-year to ₹10 billion, supported by broad-based demand across geographies. The North American business, including the United States and Canada, grew revenues by 21% year-on-year to ₹33.1 billion, driven by volume expansion and the scale-up of the US specialty pharmaceutical business.

US generics activities included filing 4 ANDAs, receiving 12 approvals, and launching 5 new products during the quarter. Notably, the company launched the first generic version of Riociguat tablets in October 2026. Specialty business growth was supported by the addition of Rolvedon through the acquisition of Assertio Holdings and traction in 505(b)(2) products.

The consumer wellness segment posted revenues of ₹11.2 billion, up 76% year-on-year. Domestic demand showed a steady urban recovery and improved rural sales, with skin and hair care plus food and nutrition portfolios delivering strong double-digit growth.

Operating profit remained strong with EBITDA at ₹18.9 billion. The company’s net debt to EBITDA ratio was 0.62 times as of September 30, 2026, and it continued to work with the USFDA to address observations from recent manufacturing facility inspections.

Highlights

  • Consolidated revenue of ₹79.1 billion, a 29% increase year-on-year for Q2 FY27
  • EBITDA margin maintained at 24% despite investments for Saroglitazar US launch
  • India branded formulations grew 19% year-on-year, with a 20% increase in secondary sales
  • International markets formulations revenue increased by 33% year-on-year to ₹10 billion
  • North America business revenue of ₹33.1 billion, up 21% year-on-year, driven by generics and specialty portfolio expansion
  • Launched 5 new US products including the first generic Riociguat tablets in October 2026 post-quarter end launch is notable future point but not for Q2 report itself; here for context only [excluded from highlights] to avoid inconsistency )

Key Data Snapshot

Consolidated revenue Q2 FY27₹79.1 billion
Year-on-year revenue growth29%
EBITDA margin Q2 FY2724%
EBITDA Q2 FY27₹18.9 billion
Net profit Q2 FY27₹9.3 billion
Net debt to EBITDA ratio as of September 30, 20260.62 times
India branded formulations growth19% year-on-year
Secondary sales growth in India formulations20% year-on-year
International formulations revenue Q2 FY27₹10 billion
International formulations growth33% year-on-year
North America revenue Q2 FY27₹33.1 billion
North America revenue growth21% year-on-year
Consumer wellness revenue Q2 FY27₹11.2 billion
Consumer wellness growth76% year-on-year

What happened

  • Zydus Lifesciences reported consolidated revenues of ₹79.1 billion for Q2 FY27, a 29% increase year-on-year.
  • EBITDA margin was maintained at 24% despite continued investments in the US Saroglitazar launch.
  • Net profit for the quarter was ₹9.3 billion.
  • Net debt to EBITDA ratio stood at 0.62 times as on September 30, 2026.

Financial performance

  • India branded formulations business grew 19% year-on-year, outperforming the Indian pharmaceutical market with 20% growth in secondary sales.
  • International formulations segment delivered ₹10 billion revenue, up 33% year-on-year.
  • North America pharmaceutical business recorded ₹33.1 billion revenue, growing 21% year-on-year.
  • Consumer wellness segment revenues increased 76% year-on-year to ₹11.2 billion.

Operational performance

  • US generics division filed 4 ANDAs, received 12 approvals, and launched 5 new products during the quarter including the launch of generic Riociguat tablets in October 2026 post quarter.
  • US specialty business expanded driven by Rolvedon addition and 505(b)(2) product portfolio.
  • USFDA inspections of key manufacturing sites resulted in one observation at SEZ-II Ahmedabad and five at Moraiya; company is addressing them.
  • A key transdermal patch approval was received on October 21, 2026.

More News on Earnings Call Transcript

View all

Latest corporate announcements and market updates in Earnings Call Transcript.

View all news
Zydus Lifesciences Achieves ₹79.1 Billion Revenue in Q2 | Stockk News